Amiodarone (amiodarone hydrochloride) tablets 0.2 g. №30

Amiodaronum (amiodarone hydrochloride) tablets 0.2 g. №30

$9.00

Manufacturer: Ukraine

Class III antiarrhythmic drugs. ATX code С01B D01.

Relapse prevention:

  • ventricular tachycardia, which poses a threat to the patient’s life: treatment must be started in a hospital with constant monitoring of the patient’s condition;
  • symptomatic ventricular tachycardia (documented), which leads to disability;
  • supraventricular tachycardia (documented), which requires treatment, and in cases where other drugs are ineffective or contraindicated;
  • ventricular fibrillation.

Treatment of supraventricular tachycardia: slowing or reducing atrial fibrillation or flutter.

Ischemic heart disease and / or dysfunction of the left ventricle.

Category:

Description

Ingredients

active ingredient: 1 tablet contains amiodarone hydrochloride 200 mg;

excipients: lactose, microcrystalline cellulose, corn starch, croscarmellose sodium, povidone, magnesium stearate.

Dosage form

Pills.

Basic physical and chemical properties: tablets of a round shape with a flat surface with beveled edges and a dash, white or almost white.

Pharmacotherapeutic group

Class III antiarrhythmic drugs. ATX code С01B D01.

Pharmacodynamics

Antiarrhythmic properties.

Prolongation of the III phase of the action potential of cardiomyocytes is mainly due to a decrease in the current of potassium ions (class III according to the Vaughan-Williams classification).

The slowing of the heart rate occurs due to the suppression of the automatism of the sinus node. This effect is not blocked by atropine.

Non-competitive alpha and beta antiadrenergic action.

Slowdown of sinoatrial, atrial and nodal impulse conduction in the myocardium, which is even more pronounced, the faster the rhythm.

No changes in intraventricular conduction.

An increase in the refractory period and a decrease in myocardial excitability at the atrial, nodal and ventricular levels.

Slow conduction and prolongation of refractory periods in accessory atrioventricular pathways.

Other properties.

Decrease in oxygen consumption through a moderate decrease in peripheral vascular resistance and a decrease in heart rate.

An increase in coronary blood flow due to a direct effect on the smooth muscles of the myocardial vessels to maintain cardiac output against the background of low blood pressure and peripheral vascular resistance, as well as in the absence of negative inotropic effects.

Indications

Relapse prevention:

  • ventricular tachycardia, which poses a threat to the patient’s life: treatment must be started in a hospital with constant monitoring of the patient’s condition;
  • symptomatic ventricular tachycardia (documented), which leads to disability;
  • supraventricular tachycardia (documented), which requires treatment, and in cases where other drugs are ineffective or contraindicated;
  • ventricular fibrillation.

Treatment of supraventricular tachycardia: slowing or reducing atrial fibrillation or flutter.

Ischemic heart disease and / or dysfunction of the left ventricle.

Contraindications

  • Sinus bradycardia, sinoatrial heart block in the absence of a pacemaker.
  • Weak sinus syndrome in the absence of an endocardial pacemaker (risk of sinus arrest).
  • Violation of AV conduction of a high degree in the absence of an endocardial pacemaker.
  • Hyperthyroidism – due to a possible exacerbation when taking amiodarone.
  • Hypersensitivity to iodine, amiodarone or any of the excipients.
  • During pregnancy and breastfeeding.

Combination with drugs that can cause paroxysmal ventricular tachycardia of the “torsades de pointes” type (with the exception of antiparasitics, antipsychotics and methadone):

  • class Ia antiarrhythmics (quinidine, hydroquinidine, disopyramide)
  • class III antiarrhythmics (sotalol, dofetilide, ibutilide)
  • other medicines such as arsenic compounds, bepridil, cisapride, citalopram, escitalopram, diphemanil, dolasetron (intravenously), domperidone, dronedarone,
  • erythromycin (intravenously), levofloxacin, mechitazine, mizolastine, moxifloxacin, prucalopride, spiramycin (c), toremifene, vincamine (c) (see section “Interaction with other medicinal products and other forms of interaction”);
  • telaprevir;
  • cobicistat.

Dosage and administration

Initial treatment. The usual recommended dose of the drug is 200 mg (1 tablet) 3 times a day for 8-10 days. In some cases, higher doses (4-5 tablets per day) can be used for initial treatment, but always for a short period of time and under electrocardiographic control.

Supportive care.  The lowest effective dose should be used. Depending on the patient’s response to the use of amiodarone hydrochloride 200 mg, the maintenance dose can be from ½ tablet per day (1 tablet every 2 days) to 2 tablets per day.

Related products